All analyses
AI analysis

Asiri Hospitals Ltd.: research report

Fairly valuedbullishOct 18, 2026

Evidence points to a stronger business than the current valuation suggests: June net margin was the best of seven comparable June quarters. The catch is only 59 cents of short-term assets for each rupee due within a year.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bullish

  • June net margin reached 14.3%, the best of seven comparable June quarters, while revenue grew 9.1% year-on-year.
  • The shares trade at 5.7 times trailing earnings, cheaper than 99% of days since February 2012.
  • The June gross margin of 51.0% was also the best of seven comparable June quarters despite being the historically weakest quarter for this measure.

Against this. The current ratio was 0.59, leaving less short-term assets than bills falling due within a year.

Net margin
18.1%sector 13.0%
from 12.9% a year earlier, revenue +24.9%
Return on equity
11.7%sector 11.2%
full year to Mar 31, 2026
P/E
6.1sector 11.8
earnings Rs 5.07 per share, year to Sep 2026
P/B
1.31sector 1.36
book Rs 23.59 per share
Dividend yield
0.00%sector 0.00%
trailing twelve months

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Oct 18, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Asiri Health operates a nationwide private hospital, diagnostics and healthcare education network. The latest June quarter extended the recovery in revenue and net profit, while operating profit eased, leaving the key question as whether stronger clinical and diagnostic volumes can continue to translate into operating profit after finance costs, tax and other charges.

Price performance

At LKR 25.00 on 16 October 2026, ASIR had fallen 26.7% over three months, against a 5.9% decline in the ASPI over the same period. The share sat 7.1% of the way up its 52-week range, close to its recent low rather than its high.

The record since October 2023 shows three falls of 15% or more, with the deepest 49% and not yet recovered. Median daily turnover was LKR 2.7 million, and a LKR 1 million order is about 37% of what trades on a typical day, a large part of a day's trading.

Valuation

At 5.7 times P/E, the market pays LKR 5.70 for each LKR 1 of trailing profit, versus a healthcare-peer median of 12.24 times. At 1.12 times P/B, it pays LKR 1.12 for each LKR 1 of net assets, below the sector median of 1.98 times; the latest audited return on equity was 11.7%, which helps explain why the shares do not trade at a deep discount to book.

Both P/E and P/B are cheaper than 99% of days since February 2012. A buyer at this price is relying on earnings that include 25.7% from the latest quarter, although that quarter's net margin was virtually unchanged from a year earlier. The market-wide valuation score is 51 of 100, placing ASIR in the fairly valued band, while the company-specific record and sector comparisons are markedly cheaper. The dividend yield is 0.0%, and no dividend is on record in the last two years.

News and sentiment

Direct coverage is thin: there were three material articles in the past 90 days, including two negative and one neutral. A 17 October article reported that Asiri Central Hospital disputed social-media allegations concerning a patient death and said it would cooperate with authorities; the report gives no financial impact.

Financials

June-quarter revenue rose 9.1% year-on-year to LKR 9.5 billion and net profit rose 11.1% to LKR 1.4 billion, even as operating profit fell 5.1%. Gross margin was 51.0% versus 50.9% a year earlier, operating margin was 20.3% versus 23.4%, and net margin was 14.3% versus 14.1%. The net margin was the best of seven comparable June quarters, so the profit attributable to the shares improved despite weaker operating profit.

June has been the weakest quarter for gross margin on average over the six complete years on record, yet this June's gross margin was the best of seven comparable June quarters. The LKR 570 million gap between operating and net profit narrowed from LKR 810 million a year earlier, helping net profit rise. Total equity reached LKR 27.9 billion from LKR 25.9 billion a year earlier, while shares outstanding remained 1.14 billion. Minority shareholders received 9.3% of the latest annual profit, so group profit is not wholly attributable to ordinary shareholders.

Risks

The leading risk is short-term funding pressure. The latest audited current ratio was 0.59, meaning the group had LKR 0.59 of assets expected to turn into cash within a year, including receivables and inventories, for each LKR 1 of bills due in that year. This leaves cash collection and lender support more important than usual.

Debt was LKR 14.0 billion, equal to 58.9% of owners' equity, and operating profit covered the interest bill 2.87 times. Gearing improved from 76.9% a year earlier, but interest still absorbs a meaningful share of operating earnings. Annual operating cash flow was 0.65 times operating profit, meaning not all reported operating profit arrived as cash. Healthcare-sector reporting also points to household-budget pressure and changing state healthcare provision, though the supplied data does not quantify a direct effect on Asiri.

Outlook

As at 18 October 2026, the next event is the September 2026 interim filing, expected between 6 and 14 November. It will show whether the June operating-profit decline was temporary while revenue and net profit continued to grow, and whether the short-term balance-sheet position has improved.

The available data cannot establish the financial effect of the medical-negligence allegations reported on 17 October, or whether sector policy changes will affect Asiri's patient volumes or pricing.

About this report. Generated on Oct 18, 2026 from market data up to Oct 16, 2026, 3 material news articles over 90 days and financials to Jun 30, 2026, and scored 51 of 100 on value (fairly valued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports